10x Genomics, Inc. (TXG) — Financial statements
Income statement, balance sheet, and cash flow for 10x Genomics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 643↑5.2% | 611↓1.3% | 619↑19.8% | 516↑5.3% | 490 | |
| Cost of Revenue | 199↑1.3% | 196↓6.3% | 209↑74.0% | 120↑62.5% | 74 | |
| Gross Profit | 444↑7.1% | 414↑1.3% | 409↑3.4% | 396↓4.9% | 416 | |
| Operating Expenses | ||||||
| R&D Expenses | 239↓9.8% | 265↓2.1% | 270↑1.8% | 266↑25.5% | 212 | |
| General & Administrative Expenses | 0.00↓100.0% | 339 | 0.00↓100.0% | 295↑16.5% | 253 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 4 | 0.00↓100.0% | 4↓21.3% | 5 | |
| SG&A Expenses | 316↓8.2% | 344↑0.3% | 343↑15.1% | 298↑15.8% | 258 | |
| Other Expenses | 0.00 | 0.00↓100.0% | 61 | 0.00 | 0.00 | |
| Operating Expenses | 555↓8.9% | 609↓9.7% | 675↑19.6% | 564↑20.2% | 469 | |
| Total Costs & Expenses | 754↓6.4% | 805↓8.9% | 884↑29.2% | 684↑25.9% | 543 | |
| Operating Results | ||||||
| Operating Income | -111↑43.0% | -195↑26.7% | -265↓58.0% | -168↓217.4% | -53 | |
| Depreciation & Amortization | 0.00↓100.0% | 44↑0.2% | 44↑32.2% | 33↑16.8% | 28 | |
| EBITDA | -111↑17.2% | -134↑34.7% | -205↓59.6% | -128↓422.4% | -25 | |
| EBIT | -111↑37.6% | -178↑28.6% | -249↓54.0% | -161↓205.6% | -53 | |
| Interest & Other Income | ||||||
| Net Interest Income | 20↑8.7% | 18↑9.3% | 17↑173.4% | 6↑1035.0% | -0.66 | |
| Interest Income | 20↑8.7% | 18↑9.1% | 17↑154.3% | 7↑3126.7% | 0.21 | |
| Interest Expense | 0.00↓100.0% | 0.00↓87.9% | 0.03↓93.1% | 0.48↓45.0% | 0.87 | |
| Non-Operating Income | 0.00↑100.0% | -17↓1.6% | -17↓157.4% | -6↓9976.6% | -0.06 | |
| Other Income / Expenses | 71↑321.0% | 17↑1.8% | 17↑177.3% | 6↑844.8% | -0.80 | |
| Income Before Tax | -40↑77.5% | -178↑28.6% | -249↓53.6% | -162↓201.5% | -54 | |
| Income Tax Expense | 4↓26.2% | 5↓22.2% | 6↑57.3% | 4↓10.6% | 5 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -44↑76.2% | -183↑28.4% | -255↓53.7% | -166↓185.1% | -58 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -44↑76.2% | -183↑28.4% | -255↓53.7% | -166↓185.1% | -58 | |
| Bottom-Line Net Income | -44↑76.2% | -183↑28.4% | -255↓53.7% | -166↓185.1% | -58 | |
| EPS (Basic) | -0.35↑77.0% | -1.52↑30.3% | -2.18↓49.3% | -1.46↓175.5% | -0.53 | |
| EPS (Diluted) | -0.35↑77.0% | -1.52↑30.3% | -2.18↓49.3% | -1.46↓175.5% | -0.53 | |
| Weighted Average Shares | 125↑3.6% | 120↑2.8% | 117↑2.9% | 114↑3.2% | 110 | |
| Weighted Average Diluted Shares | 125↑3.6% | 120↑2.8% | 117↑2.9% | 114↑3.2% | 110 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.